Literature DB >> 24310907

Antidepressants reduce neuroinflammatory responses and astroglial alpha-synuclein accumulation in a transgenic mouse model of multiple system atrophy.

Elvira Valera1, Kiren Ubhi, Michael Mante, Edward Rockenstein, Eliezer Masliah.   

Abstract

Multiple system atrophy (MSA) is a neurodegenerative disease characterized by the pathological accumulation of alpha-synuclein (α-syn) within oligodendroglial cells. This accumulation is accompanied by neuroinflammation with astrogliosis and microgliosis, that leads to neuronal death and subsequent parkinsonism and dysautonomia. Antidepressants have been explored as neuroprotective agents as they normalize neurotrophic factor levels, increase neurogenesis and reduce neurodegeneration, but their anti-inflammatory properties have not been fully characterized. We analyzed the anti-inflammatory profiles of three different antidepressants (fluoxetine, olanzapine and amitriptyline) in the MBP1-hα-syn transgenic (tg) mouse model of MSA. We observed that antidepressant treatment decreased the number of α-syn-positive cells in the basal ganglia of 11-month-old tg animals. This reduction was accompanied with a similar decrease in the colocalization of α-syn with astrocyte markers in this brain structure. Consistent with these results, antidepressants reduced astrogliosis in the hippocampus and basal ganglia of the MBP1-hα-syn tg mice, and modulated the expression levels of key cytokines that were dysregulated in the tg mouse model, such as IL-1β. In vitro experiments in the astroglial cell line C6 confirmed that antidepressants inhibited NF-κB translocation to the nucleus and reduced IL-1β protein levels. We conclude that the anti-inflammatory properties of antidepressants in the MBP1-hα-syn tg mouse model of MSA might be related to their ability to inhibit α-syn propagation from oligodendrocytes to astroglia and to regulate transcription factors involved in cytokine expression. Our results suggest that antidepressants might be of interest as anti-inflammatory and α-syn-reducing agents for MSA and other α-synucleinopathies.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Keywords:  anti-inflammation; astroglia; chemokine; cytokine; neurodegenerative disease

Mesh:

Substances:

Year:  2013        PMID: 24310907      PMCID: PMC4183229          DOI: 10.1002/glia.22610

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  163 in total

1.  Inhibition of lymphocyte trafficking shields the brain against deleterious neuroinflammation after stroke.

Authors:  Arthur Liesz; Wei Zhou; Éva Mracskó; Simone Karcher; Henrike Bauer; Sönke Schwarting; Li Sun; Dunja Bruder; Sabine Stegemann; Adelheid Cerwenka; Clemens Sommer; Alexander H Dalpke; Roland Veltkamp
Journal:  Brain       Date:  2011-03       Impact factor: 13.501

2.  Lithium protects against oxidative stress-mediated cell death in α-synuclein-overexpressing in vitro and in vivo models of Parkinson's disease.

Authors:  Yong-Hwan Kim; Anand Rane; Stephanie Lussier; Julie K Andersen
Journal:  J Neurosci Res       Date:  2011-06-24       Impact factor: 4.164

3.  Interleukin-10 inhibits both production of cytokines and expression of cytokine receptors in microglia.

Authors:  M Sawada; A Suzumura; H Hosoya; T Marunouchi; T Nagatsu
Journal:  J Neurochem       Date:  1999-04       Impact factor: 5.372

4.  Interleukin-10 prevents glutamate-mediated cerebellar granule cell death by blocking caspase-3-like activity.

Authors:  A Bachis; A M Colangelo; S Vicini; P P Doe; M A De Bernardi; G Brooker; I Mocchetti
Journal:  J Neurosci       Date:  2001-05-01       Impact factor: 6.167

5.  Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

Authors:  D Blum-Degen; T Müller; W Kuhn; M Gerlach; H Przuntek; P Riederer
Journal:  Neurosci Lett       Date:  1995-12-29       Impact factor: 3.046

6.  Interleukin-1beta mediates proliferation and differentiation of multipotent neural precursor cells through the activation of SAPK/JNK pathway.

Authors:  Xiaofei Wang; Saili Fu; Yanxia Wang; Panpan Yu; Jianguo Hu; Wenli Gu; Xiao-Ming Xu; Peihua Lu
Journal:  Mol Cell Neurosci       Date:  2007-07-24       Impact factor: 4.314

7.  Antidepressants are a rational complementary therapy for the treatment of Alzheimer's disease.

Authors:  Marwa Aboukhatwa; Laura Dosanjh; Yuan Luo
Journal:  Mol Neurodegener       Date:  2010-03-12       Impact factor: 14.195

8.  Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils.

Authors:  Hilal A Lashuel; Benjamin M Petre; Joseph Wall; Martha Simon; Richard J Nowak; Thomas Walz; Peter T Lansbury
Journal:  J Mol Biol       Date:  2002-10-04       Impact factor: 5.469

9.  Interleukin-1 mediates Alzheimer and Lewy body pathologies.

Authors:  W Sue T Griffin; Ling Liu; Yuekui Li; Robert E Mrak; Steven W Barger
Journal:  J Neuroinflammation       Date:  2006-03-16       Impact factor: 8.322

10.  Lithium induces autophagy by inhibiting inositol monophosphatase.

Authors:  Sovan Sarkar; R Andres Floto; Zdenek Berger; Sara Imarisio; Axelle Cordenier; Matthieu Pasco; Lynnette J Cook; David C Rubinsztein
Journal:  J Cell Biol       Date:  2005-09-26       Impact factor: 10.539

View more
  30 in total

1.  Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form.

Authors:  Timothy J Collier; Kinshuk R Srivastava; Craig Justman; Tom Grammatopoulous; Birgit Hutter-Paier; Manuela Prokesch; Daniel Havas; Jean-Christophe Rochet; Fang Liu; Kevin Jock; Patrícia de Oliveira; Georgia L Stirtz; Ulf Dettmer; Caryl E Sortwell; Mel B Feany; Peter Lansbury; Lisa Lapidus; Katrina L Paumier
Journal:  Neurobiol Dis       Date:  2017-07-12       Impact factor: 5.996

2.  Chronic amitriptyline treatment attenuates nigrostriatal degeneration and significantly alters trophic support in a rat model of parkinsonism.

Authors:  Katrina L Paumier; Caryl E Sortwell; Lalitha Madhavan; Brian Terpstra; Stephanie L Celano; Joshua J Green; Nastassja M Imus; Nathan Marckini; Brian Daley; Kathy Steece-Collier; Timothy J Collier
Journal:  Neuropsychopharmacology       Date:  2014-09-30       Impact factor: 7.853

Review 3.  Review: Novel treatment strategies targeting alpha-synuclein in multiple system atrophy as a model of synucleinopathy.

Authors:  E Valera; G Monzio Compagnoni; E Masliah
Journal:  Neuropathol Appl Neurobiol       Date:  2016-02       Impact factor: 8.090

Review 4.  Synaptic Loss and the Pathophysiology of PTSD: Implications for Ketamine as a Prototype Novel Therapeutic.

Authors:  John H Krystal; Chadi G Abdallah; Lynette A Averill; Benjamin Kelmendi; Ilan Harpaz-Rotem; Gerard Sanacora; Steven M Southwick; Ronald S Duman
Journal:  Curr Psychiatry Rep       Date:  2017-08-26       Impact factor: 5.285

5.  Long-term Ameliorative Effects of the Antidepressant Fluoxetine Exposure on Cognitive Deficits in 3 × TgAD Mice.

Authors:  Li Jin; Li-Feng Gao; Dong-Sheng Sun; Hao Wu; Qun Wang; Dan Ke; Hao Lei; Jian-Zhi Wang; Gong-Ping Liu
Journal:  Mol Neurobiol       Date:  2016-06-21       Impact factor: 5.590

6.  Relationships between low-grade peripheral inflammation and psychotropic drugs in schizophrenia: results from the national FACE-SZ cohort.

Authors:  G Fond; N Resseguier; F Schürhoff; O Godin; M Andrianarisoa; L Brunel; E Bulzacka; B Aouizerate; F Berna; D Capdevielle; I Chereau; T D'Amato; C Dubertret; J Dubreucq; C Faget; F Gabayet; C Lançon; P M Llorca; J Mallet; D Misdrahi; C Passerieux; R Rey; A Schandrin; M Urbach; P Vidailhet; L Boyer; M Leboyer
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-11-10       Impact factor: 5.270

Review 7.  The neuropathology of multiple system atrophy and its therapeutic implications.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Auton Neurosci       Date:  2017-11-10       Impact factor: 3.145

Review 8.  Combination therapies: The next logical Step for the treatment of synucleinopathies?

Authors:  Elvira Valera; Eliezer Masliah
Journal:  Mov Disord       Date:  2015-09-21       Impact factor: 10.338

Review 9.  Therapeutic approaches in Parkinson's disease and related disorders.

Authors:  Elvira Valera; Eliezer Masliah
Journal:  J Neurochem       Date:  2016-02-10       Impact factor: 5.372

Review 10.  Multiple system atrophy: experimental models and reality.

Authors:  Cassia Overk; Edward Rockenstein; Elvira Valera; Nadia Stefanova; Gregor Wenning; Eliezer Masliah
Journal:  Acta Neuropathol       Date:  2017-10-20       Impact factor: 17.088

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.